Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Recombinant Human Erythropoietin Injection (CHO Cell) in Renal Anemia
CTR20220540Phase 2Completed
- Sponsor
- Anderson Biopharmaceuticals
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated recombinant human erythropoietin in anemia of renal disease, sponsored by Anderson Biopharmaceuticals. Started Mar 2022; status: completed.
02
Drugs
pegylated recombinant human erythropoietin
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on CTR20220540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220540.